Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2003
11/27/2003WO2003097028A1 Use of edg receptor binding agents in cancer
11/27/2003WO2003097009A1 Injection formulation
11/27/2003WO2003096980A2 Bicyclic modulators of androgen receptor function
11/27/2003WO2003096964A2 Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
11/27/2003WO2003096782A2 Process for preparing maytansinol
11/27/2003WO2003085087A3 Modified cea nucleic acid and expression vectors
11/27/2003WO2003084464A3 Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
11/27/2003WO2003083096A3 Cancer associated protein kinases and their uses
11/27/2003WO2003082189A3 Method for producing pseudo islets
11/27/2003WO2003080638A9 Antisense iap nucleobase oligomers and uses thereof
11/27/2003WO2003076469A3 Antibodies derived rom anti ed-b l19 and targeting tumor vasculature
11/27/2003WO2003075841A3 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
11/27/2003WO2003074547A3 Biologically active complex comprising alpha-lcatalbumin or a variant thereof, and a cofactor
11/27/2003WO2003074508B1 Compounds and methods of treating cell proliferative diseases
11/27/2003WO2003070765A3 Growth hormone fusion protein
11/27/2003WO2003066661A3 Human dr4 antibodies and uses thereof
11/27/2003WO2003066594A3 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
11/27/2003WO2003064622A3 Aggrecanase molecules
11/27/2003WO2003059942A9 Peptides and peptidomimetics having anti-proliferative activity and their use
11/27/2003WO2003057837A3 Methods for using anti-muc18 antibodies
11/27/2003WO2003053354A3 Fused cyclic modulators of nuclear hormone receptor function
11/27/2003WO2003051879A8 Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
11/27/2003WO2003051383A3 Use of hmgb proteins and nucleic acids that code therefor
11/27/2003WO2003050252A3 Heme-regulated eukaryotic initiation factor 2 alpha kinase knockout mice and methods for use
11/27/2003WO2003047417A3 Ep4 receptor agonist, compositions and methods thereof
11/27/2003WO2003042344A3 Apo2 ligand/trail formulations
11/27/2003WO2003040119A8 Angiogenesis inhibitors
11/27/2003WO2003039446A3 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
11/27/2003WO2003035883A3 Methods and compositions for inducing tumor-specific cytotoxicity
11/27/2003WO2003032964A3 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
11/27/2003WO2003031578A3 Mammalian c-type lectins
11/27/2003WO2003030824A3 Methods and compositions for treating dermal lesions
11/27/2003WO2003029459A3 Micro-rna molecules
11/27/2003WO2003028656A3 Adjuvant compositions
11/27/2003WO2003022852A3 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
11/27/2003WO2003018598A3 Monosaccharide derivatives
11/27/2003WO2003018593A3 Platinum(ii)- and platinum(iv)-complexes and their use
11/27/2003WO2003015717A3 Tyrosine kinase inhibitors
11/27/2003WO2003015713A3 Treatment of glial tumors with glutamate antagonists
11/27/2003WO2003014144A3 Molecule
11/27/2003WO2003014102B1 Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors
11/27/2003WO2003013590A8 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
11/27/2003WO2003008443A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/27/2003WO2003008429A3 Solvent-free anthracycline derivatives
11/27/2003WO2003007888A3 Fat accumulation-modulating compounds
11/27/2003WO2003006995A3 Method for identifying substances which modulate interleukin 4 (il-4) signaling
11/27/2003WO2003006611A3 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE
11/27/2003WO2003006425A3 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
11/27/2003WO2003005971A3 Tetracycline compounds having target therapeutic activities
11/27/2003WO2003004091A3 Aromatic sulfenates for type i phototherapy
11/27/2003WO2002102299A3 Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
11/27/2003WO2002099059A3 U5-200KDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
11/27/2003WO2002094881A3 Monoclonal antibody neutralising cathepsin b activity and uses thereof
11/27/2003WO2002092771A3 Specific binding proteins and uses thereof
11/27/2003WO2002086156A3 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
11/27/2003WO2002085940A3 New polynucleotides and polypeptides of the erythropoietin gene
11/27/2003WO2002079170A3 Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing them
11/27/2003WO2002078730A3 Use of neublastin polypeptides for treating neuropathic pain
11/27/2003WO2002074735A3 Biurethane derivatives
11/27/2003WO2002064791A3 Proteins and nucleic acids encoding same
11/27/2003WO2002063010A3 Method of producing recombinant antibodies against tumors
11/27/2003WO2002061109A3 Yeast strains autonomously producing steroids
11/27/2003WO2002060950B1 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
11/27/2003WO2002057242A3 Urea derivatives as integrin alpha 4 antagonists
11/27/2003WO2002048368A3 Proteins associated with cell growth, differentiation, and death
11/27/2003WO2000062735A3 Treatment of neoplasms with viruses
11/27/2003WO2000050046A8 Stabilized oral pharmaceutical composition containing iodide and iodate and method
11/27/2003US20030221206 Using in vitro fertilization to produce gentically engineered animals for use as models for prevention and treatment of disease
11/27/2003US20030220494 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/27/2003US20030220489 29 human secreted proteins
11/27/2003US20030220483 Comprises fibroblast growth factor homologous factor- 1 (FHF-1) for disgnosing, prevention and treatment of neurodegenerative or neoplastic disorders
11/27/2003US20030220480 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
11/27/2003US20030220478 Novel compounds
11/27/2003US20030220476 A fusion proteins comprising a cyclic peptide linked to a receptor as a cell growth factors, promoting cell proliferation, cell antiproliferative agents; soluble, potent
11/27/2003US20030220473 An antitumor agent of polynucleotide sequence, a vector, a genetic construct, for encoding a protein
11/27/2003US20030220468 Modified forms of pharmacologically active agents and uses therefor
11/27/2003US20030220405 DNA encoding an epsilon, epsilon-lycopene cyclase from romaine lettuce
11/27/2003US20030220402 Secondary carbocyclic amides such as 2-(4-(2-naphthyloxy)-benzamido)benzoic acid methyl ester, used as anticarcinogenic agents
11/27/2003US20030220388 Indoline derivatives
11/27/2003US20030220387 Nitrogen compounds such as 3,9-Difluoro-12,13-dihydro-13-((3,6 -anhydro)-beta-D- glucopyranosyl)-5H-indolo(2,3-a)pyrrolo(3,4 -c)carbazole-5,7(6H)-dione, used as topoisomerase inhibitors, antiproliferative or antitumor agents
11/27/2003US20030220382 Amines such as 2-((2-N,N-di-n-pentylamino)-indan-5-yl)amino-5 -nitro-benzoic acid, administered for prophylaxis of Alzheimer's disease
11/27/2003US20030220379 Fermentative preparation process for and crystal forms of cytostatics
11/27/2003US20030220375 N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
11/27/2003US20030220372 Imidazole compounds as anti-inflammatory and analgesic agents
11/27/2003US20030220371 Administering to a mammal an aromatic or heteroaromatic ring substituted triazole derivative to treat the conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, and obesity
11/27/2003US20030220359 Substituted pyrimidine-sulfonamide derivatives are used as endothelin receptor antagonists
11/27/2003US20030220354 Quinazoline ditosylate salt compounds
11/27/2003US20030220353 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/27/2003US20030220349 Related to organ systems which respond to estrogen agonists or antagonists; in particular, 2-phenyl-3-aroylbenzothiophenes and 1-(alkylaminoethoxy phenyl)-1-phenyl-2-phenylbut-1-enes have wide application as estrogen agonists
11/27/2003US20030220345 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones
11/27/2003US20030220341 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
11/27/2003US20030220339 Heterocyclic arylsulfonamidobenzylic compounds
11/27/2003US20030220330 Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
11/27/2003US20030220326 Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases
11/27/2003US20030220320 Ningalin b analogs employable for reversing multidrug resistance
11/27/2003US20030220297 Phosphorus-containing compounds and uses thereof
11/27/2003US20030220295 Epothilone derivatives
11/27/2003US20030220279 Decreasing cell proliferation by decreasing levels of PP5
11/27/2003US20030220270 Mono-and disaccharide derivatives
11/27/2003US20030220268 New phenylalanine derivatives
1 ... 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 ... 2211